Galvanize Therapeutics launches first commercial procedures with Aliya EX System, expanding pulsed electric field ablation into percutaneous and endoscopic cardiac interventions
Executive summary: Galvanize Therapeutics announced the first commercial procedures using its Aliya EX System, a next-generation pulsed electric field (PEF) ablation device capable of both percutaneous and endoscopic delivery, on August 11, 2026, with public release on August 12. The launch expands the clinical applicability of PEF ablation beyond traditional catheter-based methods, potentially enabling treatment of complex cardiac arrhythmias in broader patient populations and reducing reliance on thermal energy sources that carry risks of collateral damage.
Who is involved: Galvanize Therapeutics, Inc. (Redwood City, Calif.), interventional cardiologists and electrophysiologists conducting the procedures, and patients receiving treatment under commercial use.
Likely next: Accumulation of real-world safety and efficacy data from early commercial cases, potential submission of additional clinical evidence to support regulatory expansions, and increased competition from other PEF developers like Medtronic and Boston Scientific advancing similar platforms.
Galvanize Therapeutics has initiated the first commercial use of its next-generation Aliya EX System, a pulsed electric field (PEF) ablation platform designed for both percutaneous and endoscopic delivery. This marks a significant step in broadening access to minimally invasive cardiac tissue ablation beyond traditional surgical or catheter-based approaches. The system’s dual-modality capability positions it to address unmet needs in complex arrhythmia treatment, particularly in patients unsuitable for conventional procedures. While clinical data supporting safety and efficacy were not detailed in the announcement, the move reflects growing commercial momentum in PEF technology following early adopter success in Europe and ongoing FDA review pathways.
Timeline
- — Galvanize Therapeutics® Announces First Commercial Procedures Using the New Aliya® EX System (PR Newswire)
Analysis — what this means
Likely next events
- FDA review of supplemental PMA data for Aliya EX System expected by Q1 2027
- First peer-reviewed outcomes from commercial cases anticipated in Q4 2026
- Medtronic to report early feasibility results of its PEF platform by end of 2026
Sectors affected
- Cardiac ablation devices
- Minimally invasive surgery
- Electrophysiology diagnostics and treatment
Regulatory implications
- FDA may require post-market study data for expanded endoscopic indications under Section 522 of FD&C Act
- Reimbursement pathways via CMS likely to follow CPT code updates anticipated in 2027
- ISO 14708-3 compliance for implantable pulse generators may influence future system iterations
Historical parallels
- Launch of Medtronic’s Arctic Front cryoablation system in 2009 expanded AF treatment beyond radiofrequency
- Introduction of Biosense Webster’s CartoMerge imaging integration in 2016 improved procedural accuracy in complex substrates
- First commercial use of Faraday Therapeutics’ transcatheter PEF system in EU 2024 preceded U.S. IDE approval
Sources
- Galvanize Therapeutics® Announces First Commercial Procedures Using the New Aliya® EX System — PR Newswire
Related cases
- Karmanos Cancer Institute begins offering the newly FDA‑approved KRAS G12C inhibitor daraxonrasib (Rasonque) for metastatic pancreatic cancer, marking the first clinical rollout of a targeted therapy for a historically hard‑to‑treat malignancy
- FDA clears Caliway's CBL-514 combo with tirzepatide for Phase 2 trial as pivotal Phase 3 SUPREME-01 starts enrollment
- FDA’s approval of IMAAVY provides the first-ever drug for warm autoimmune hemolytic anemia, creating a new niche in rare disease therapeutics
- FDA approves Implantica's RefluxStop, clearing the way for US market entry of a new GERD treatment device
- FDA approval clears the way for Implantica’s RefluxStop to enter the U.S. GERD treatment market
- AbelZeta regains global rights to C‑CAR039 (Prizlon‑cel) and secures FDA IND clearance for large B‑cell lymphoma therapy